1. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2014;311(3):252-262. doi:10.1001/jama.2013.282836 Flow of Patients Through the TrialLDL-C indicates low-density lipoprotein cholesterol. Figure Legend:

2. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2014;311(3):252-262. doi:10.1001/jama.2013.282836 Median Levels of Lipid Parameters and Log CRP in Patients Treated With Placebo and VarespladibCRP indicates C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein. Error bars for LDL-C and HDL-C represent standard errors. Error bars for triglycerides and log CRP represent interquartile ranges. P values for LDL-C, HDL-C, and CRP are by t test. P value for triglycerides is by Wilcoxon rank sum test for percentage change. Figure Legend:

3. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2014;311(3):252-262. doi:10.1001/jama.2013.282836 Kaplan-Meier Survival Curves for the Primary Composite Outcome and Myocardial Infarction in Patients Treated With Placebo and VarespladibThe primary efficacy outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Patients were randomized to receive either varespladib (500 mg/d) or placebo for 16 weeks. HR indicates hazard ratio. Y-axis scale shown in blue indicates range from 0% to 4%. Figure Legend:

4. Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2014;311(3):252-262. doi:10.1001/jama.2013.282836 Comparison of the Effects of Varespladib and Placebo on the Incidence of Primary Composite Outcome and Myocardial Infarction in Prespecified Subgroup Patient CharacteristicsThe primary efficacy outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Patients were randomized to receive either varespladib (500 mg/d) or placebo for 16 weeks. Non-STEMI indicates non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction. Because of missing data, number of patients in the subgroups do not sum to total number of patients randomized to receive placebo or varespladib. Figure Legend: